Melania Czyżewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melania Czyżewicz has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Cieplak
University Clinical Center named after Prof. K. Gibiński, ul. Medyków 14, 40-514 Katowice, Poland
1 shared publication - Aleksandra Kołodziej
Municipal Hospital No. 4 in Gliwice ul. Zygmunta Starego 20, 44-100 Gliwice, Poland
1 shared publication - Nadia Hornig
Independent Public Health Care Facility of the Ministry of Internal Affairs and Administration in Katowice named after Sergeant Grzegorz Załoga, ul. Wita Stwosza 39-41 40-042 Katowice, Poland
1 shared publication - Wiktoria Zamirska
Katowice Oncology Centre, ul. Raciborska 26, 40-074 Katowice, Poland
1 shared publication - Zuzanna Czyżewicz
Medical University of Silesia, ul. Poniatowskiego 15, 40-055 Katowice, Katowice, Poland
1 shared publication
Latest Publications
- Open Access
- 5 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60223
Androgenetic alopecia - a literature review
Introduction and Purpose: Androgenetic alopecia (AGA) is the most common form of hair loss, affecting both men and women. It involves progressive miniaturization of hair follicles due to dihydrotestosterone (DHT) and genetic factors. AGA has cosmetic and psychological impacts and is linked to systemic conditions such as cardiovascular and metabolic disorders. Although treatments like finasteride and minoxidil are FDA-approved, alternative therapies are being explored to improve outcomes and reduce side effects. This review provides an updated overview of AGA pathogenesis and emerging treatment options. Material and Methods: A comprehensive literature review was conducted, analyzing recent studies on AGA pathophysiology, genetics, and treatments. Findings on FDA-approved drugs, alternative pharmacologic therapies, mesotherapy, and low-level light therapy (LLLT) were evaluated for efficacy and safety. State of Knowledge: AGA pathogenesis includes hormonal, genetic, and environmental components. DHT binds to androgen receptors in vulnerable hair follicles, leading to miniaturization. Genetic susceptibility involves loci like AR/EDA2R. While finasteride and minoxidil remain mainstays, newer treatments—such as dutasteride, androgen receptor antagonists (e.g., spironolactone, clascoterone, pyrilutamide), mesotherapy, and low-dose oral minoxidil—show promise. LLLT, particularly red LED light (630–660 nm), stimulates hair growth and reduces inflammation. Clinical studies suggest combination therapies are more effective than monotherapy. Conclusions: AGA is complex and requires long-term management. Finasteride and minoxidil are effective, but alternative treatments like dutasteride, mesotherapy, androgen blockers, and red LED therapy offer promising results. Combination therapy appears most effective, though more research is needed to standardize protocols and confirm long-term safety.
- 5 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60223
Open AccessAndrogenetic alopecia - a literature review
Introduction and Purpose: Androgenetic alopecia (AGA) is the most common form of hair loss, affecting both men and women. It involves progressive miniaturization of hair follicles due to dihydrotestosterone (DHT) and genetic factors. AGA has cosmetic and psychological impacts and is linked to systemic conditions such as cardiovascular and metabolic disorders. Although treatments like finasteride and minoxidil are FDA-approved, alternative therapies are being explored to improve outcomes and reduce side effects. This review provides an updated overview of AGA pathogenesis and emerging treatment options. Material and Methods: A comprehensive literature review was conducted, analyzing recent studies on AGA pathophysiology, genetics, and treatments. Findings on FDA-approved drugs, alternative pharmacologic therapies, mesotherapy, and low-level light therapy (LLLT) were evaluated for efficacy and safety. State of Knowledge: AGA pathogenesis includes hormonal, genetic, and environmental components. DHT binds to androgen receptors in vulnerable hair follicles, leading to miniaturization. Genetic susceptibility involves loci like AR/EDA2R. While finasteride and minoxidil remain mainstays, newer treatments—such as dutasteride, androgen receptor antagonists (e.g., spironolactone, clascoterone, pyrilutamide), mesotherapy, and low-dose oral minoxidil—show promise. LLLT, particularly red LED light (630–660 nm), stimulates hair growth and reduces inflammation. Clinical studies suggest combination therapies are more effective than monotherapy. Conclusions: AGA is complex and requires long-term management. Finasteride and minoxidil are effective, but alternative treatments like dutasteride, mesotherapy, androgen blockers, and red LED therapy offer promising results. Combination therapy appears most effective, though more research is needed to standardize protocols and confirm long-term safety.